Differences

This shows you the differences between two versions of the page.

--- stanley_plotkin [2022/10/20 02:41]
liam [History]
+++ stanley_plotkin [2023/01/22 05:10] (current)
liam
@@ Line 7: / Line 7: @@
 ===== History =====
-In July 2015, the [[New England Journal of Medicine]] published a paper co-authored by Plotkin, [[Jeremy Farrar]] and [[Adel Mahmoud]], calling for the formation of a global funding mechanism for [[vaccine]] development.((Plotkin, S. A., Mahmoud, A. A. F., & Farrar, J. (2015). //Establishing a Global Vaccine-Development Fund.// New England Journal of Medicine, 373(4), 297–300. https://doi.org/10.1056/nejmp1506820)) This idea later became the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) which launched at the [[World Economic Forum]] in 2017 with funding from [[Wellcome Trust]], the [[Bill & Melinda Gates Foundation]] and a number of national governments.(())
+In July 2015, the [[New England Journal of Medicine]] published a paper co-authored by Plotkin, [[Jeremy Farrar]] and [[Adel Mahmoud]], calling for the formation of a global funding mechanism for [[vaccine]] development.((Plotkin, S. A., Mahmoud, A. A. F., & Farrar, J. (2015). //Establishing a Global Vaccine-Development Fund.// New England Journal of Medicine, 373(4), 297–300. https://doi.org/10.1056/nejmp1506820)) This idea later became the [[Coalition for Epidemic Preparedness Innovations]] (CEPI) which launched at the [[World Economic Forum]] in 2017 with funding from [[Wellcome Trust]], the [[Bill & Melinda Gates Foundation]] and a number of national governments.((Solberg, E. (2017, January 20). //$460 Million Coalition for Epidemic Preparedness Innovation Launched.// Philanthropy News Digest. https://web.archive.org/web/20220112055033/https://philanthropynewsdigest.org/news/460-million-coalition-for-epidemic-preparedness-innovation-launched))
 ===== Affiliations =====
 ==== Pharmaceutical companies ====
-In a 2015 disclosure of interest, Plotkin revealed he received personal fees from [[pharmaceutical_companies:Dynavax]], [[pharmaceutical_companies:Emergent BioSolutions]], [[pharmaceutical_companies:Geovax]], [[pharmaceutical_companies:HOOKIPA Pharma]], [[pharmaceutical_companies:Inovio]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi Pasteur]].((Plotkin, S. (2015). //ICMJE Form for Disclosure of Potential Conflicts of Interest// (p. 8). New England Journal of Medicine. https://web.archive.org/web/20221020003030/https://www.nejm.org/doi/suppl/10.1056/NEJMp1506820/suppl_file/nejmp1506820_disclosures.pdf))
+In a 2015 disclosure of interest, Plotkin revealed he received personal fees from [[pharmaceutical_companies:Dynavax]], [[pharmaceutical_companies:Emergent BioSolutions]], [[pharmaceutical_companies:Geovax]], [[pharmaceutical_companies:HOOKIPA Pharma]], [[pharmaceutical_companies:Inovio Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi Pasteur]].((Plotkin, S. (2015). //ICMJE Form for Disclosure of Potential Conflicts of Interest// (p. 8). New England Journal of Medicine. https://web.archive.org/web/20221020003030/https://www.nejm.org/doi/suppl/10.1056/NEJMp1506820/suppl_file/nejmp1506820_disclosures.pdf))